Abstract
Thirty-nine patients with advanced heavily pretreated epithelial carcinoma of the ovary were treated with mitoxantrone (dihydroxyanthracenedione hydrochloride). Twenty-five patients were started at a dose of 12 mg/m2 q 21d and 13 patients, with compromised bone marrow, at a dose of 10 mg/m2 q 21d. Two stable responses (6%) occurred in 31 fully evaluable patients. The median duration of survival was 17 weeks. The principal toxicity, hematopoietic (primarily leukopenia), was mild and well tolerated. We conclude that mitoxantrone is a relatively inactive drug in the treatment of epithelial ovarian carcinoma.
Original language | English (US) |
---|---|
Pages (from-to) | 499-501 |
Number of pages | 3 |
Journal | American Journal of Clinical Oncology: Cancer Clinical Trials |
Volume | 7 |
Issue number | 5 |
DOIs | |
State | Published - 1984 |
Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research